To the best of our knowledge, the present study has offered clear evidence that the Src inhibitor dasatinib preferentially inhibited the growth of breast cancer cells of the basal B subtype associated with a G1-S cell cycle blockade and a reduction in the proportion of ALDH1-positive, putative breast cancer stem cells. Here, SRC is linked to breast cancer.